Maxwell McDonald, MD
Hematology & Oncology · Shreveport, LANPI 1699764589
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $103,290 of the $123,211 with a category attached, or 83.8%. 38 manufacturers reported payments, led by AstraZeneca at 56.9% of the total. Reporting peaked in 2019 at $50,692 and has fallen 98.1% since, to $944 in 2025. Among hematology & oncology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $441.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$70K
- Merck$34K
- Genentech USA, Inc.$15K
- Novartis$2K
- AbbVie$387
- Myriad Genetic Laboratories, Inc.$238
- plus $2K from 32 others
Across 9 payments — averaging $4455.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$39K
- Bristol Myers Squibb$1K
What the payments were for
- Consulting fees$9,1837%
- Speaking & faculty fees$103,29084%
- Travel & lodging$2,4662%
- Food & beverage$6,2065%
- Education$4680%
- Other$1,5981%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 65 | $70,147 |
| Merck | 48 | $33,792 |
| Genentech USA, Inc. | 19 | $14,564 |
| Novartis | 40 | $2,025 |
| AbbVie | 19 | $387 |
| Myriad Genetic Laboratories, Inc. | 2 | $238 |
| Genmab U.S., Inc. | 2 | $229 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $219 |
| Johnson & Johnson | 8 | $198 |
| Pfizer | 11 | $194 |
| Daiichi Sankyo Inc. | 9 | $178 |
| Seagen Inc. | 1 | $100 |
| Incyte Corporation | 6 | $98 |
| Amgen | 5 | $86 |
| E.r. Squibb & Sons, L.L.C. | 5 | $65 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $61 |
| Bristol Myers Squibb | 3 | $58 |
| Tempus AI, Inc | 2 | $57 |
| Exelixis Inc. | 3 | $54 |
| GSK | 1 | $48 |
| Boehringer Ingelheim | 2 | $43 |
| Gilead | 3 | $42 |
| Mirati Therapeutics, Inc. | 2 | $40 |
| Astellas Pharma US Inc | 2 | $32 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Rigel Pharmaceuticals, Inc. | 1 | $23 |
| Sanofi | 1 | $21 |
| Tesaro, Inc. | 1 | $20 |
| Taiho Oncology, Inc. | 1 | $19 |
| Bayer | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| AMAG Pharmaceuticals, Inc. | 1 | $17 |
| Partner Therapeutics, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Clovis Oncology, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$66,573
- KEYTRUDA$32,748
- TECENTRIQ$14,443
- TIVDAK$229
- PreciseTumor$154
How this compares
$123,211 in reported general payments places this provider in the 90th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 36 | $659,952 |
| LenvimaLenvatinib Mesylate | 21 | $502,239 |
| LynparzaOlaparib | 23 | $385,036 |
| KisqaliRibociclib Succinate | 20 | $341,687 |
| VerzenioAbemaciclib | 12 | $185,817 |
| Abiraterone Acetate | 17 | $62,814 |
| Imatinib Mesylate | 11 | $59,020 |
| EliquisApixaban | 40 | $30,046 |
| XareltoRivaroxaban | 19 | $11,548 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 169 | $4,920 |
| Anastrozole | 213 | $4,256 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 85 | $3,369 |
| Letrozole | 94 | $2,101 |
| Tamoxifen Citrate | 93 | $1,996 |
| Prochlorperazine Maleate | 139 | $1,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $61 | $659,95236 claims |
| Eisai Inc.Lenvima | $15 | $502,23921 claims |
| AstraZenecaLynparza | $70,147 | $385,03623 claims |
| NovartisKisqali | $2,025 | $341,68720 claims |
| Lilly USA, LLCVerzenio | $16 | $185,81712 claims |
| PfizerEliquis | $194 | $30,04640 claims |
| Johnson & JohnsonXarelto | $198 | $11,54819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in Shreveport
- Prakash PeddiShreveport$405K
- Kevin GallagherShreveport$145K
- Kirtan KotichaShreveport$45K
- Tharwat GhattasShreveport$25K
- Joyce FeaginShreveport$19K
- Richard MansourShreveport$16K
- Kavitha BeedupalliShreveport$15K
- Steven BoniolShreveport$14K
- Gary BurtonShreveport$10K
- Hana SafahBaton Rouge$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.